Sam Klempner, Associate Professor at Harvard Medical School, shared on X:
“Adding to the ever growing approaches in GEA
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or GEJ Adenocarcinoma: DisTinGuish.”
Authors: Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg, Hope Elizabeth Uronis, Vi K. Chiu, Aaron James Scott, Syma Iqbal, Mohamedtaki Abdulaziz Tejani, Vincent Chung, Melissa C. Stilian, Mathis Thoma, Ying Zhang, Michael H. Kagey, Jason Baum, Cynthia A. Sirard, Rachel A. Altura, Jaffer A. Ajani.
